Safe DKA Treatment in Renal-Impaired Patients: EndoTool IV Insights with Dr. Aloi and Dr. Chidester. скачать в хорошем качестве

Safe DKA Treatment in Renal-Impaired Patients: EndoTool IV Insights with Dr. Aloi and Dr. Chidester.

Joseph Aloi, MD, Section Chief of Endocrinology and Metabolism at Wake Forest Baptist Health (Atrium Health), and Paul Chidester, MD, Chief Medical Officer at Monarch Medical Technologies, break down key findings from their poster, "Treatment of DKA in Patients with Decreased Renal Function" presented at the 24th Annual Diabetes Technology Meeting. They discuss key findings from their poster which analyzes the effectiveness of EndoTool patient-specific insulin dosing software in treating patients with varying levels of renal insufficiency. With a hypoglycemia risk of less than 1% and a near-zero risk of severe hypoglycemia (less than 0.01%), EndoTool IV proves to be a reliable solution for treating DKA patients with minimal risk of hypoglycemia irrespective of kidney function. To learn more, visit our website to view the full poster: https://monarchmedtech.com/evidence/u... Or contact us to discuss how EndoTool can benefit your health system: https://monarchmedtech.com/contact-us/ Subscribe now for more updates!